(Q35987747)

11 August 2017

1 reference

title

Management of muscle-invasive bladder cancer in the elderly. (English)

1 reference

11 August 2017

1 reference

Umberto Basso

1

0 references

Silvio Monfardini

object named as

Silvio Monfardini

series ordinal

4

0 references

author name string

Pierfrancesco Bassi

series ordinal

2

1 reference

PubMed ID

15606330

11 August 2017

Teodoro Sava

series ordinal

3

1 reference

11 August 2017

1 December 2004

1 reference

Expert Review of Anticancer Therapy

11 August 2017

1 reference

11 August 2017

4

1 reference

11 August 2017

1017-1035

1 reference

11 August 2017

6

1 reference

11 August 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Gender, racial and age differences in bladder cancer incidence and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Management and geriatric assessment of cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Measuring comorbidity in older cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Outcome of radical cystectomy for invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Organ preservation strategies in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Managing locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Surgery and adjunctive chemotherapy for invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Taxanes in elderly breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Evaluation of renal function in elderly cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

Molecular targeting and pharmacogenomics in the management of advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

What we could do now: molecular pathology of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1017

10.1586/14737140.4.6.1017

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15606330